Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Anavex Lf SC
(NQ:
AVXL
)
9.240
+1.605 (+21.02%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Anavex Lf SC
< Previous
1
2
3
4
5
6
7
8
Next >
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Anavex Life Sciences Corp. with Losses of $100,000 to Contact the Firm
February 02, 2022
From
The Schall Law Firm
Via
Business Wire
23 Stocks Moving in Wednesday's Pre-Market Session
February 02, 2022
Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep. Also check out: Executives buy more than $600 million of 3...
Via
Benzinga
Mid-Afternoon Market Update: Dow Rises 50 Points; DLH Holdings Shares Drop
February 01, 2022
US stocks traded mixed in the afternoon session on Tuesday after recording sharp gains in the previous session. Wall Street closed the volatile January month with steep losses.
Via
Benzinga
Anavex Life Sciences Says Rett Syndrome Trial Meets Primary & Secondary Goals
February 01, 2022
Anavex Life Sciences Corp (NASDAQ: AVXL) reported topline data from the Phase 3 AVATAR trial of ANAVEX2-73 (blarcamesine) in adult female patients with Rett syndrome.
Via
Benzinga
52 Biggest Movers From Yesterday
February 02, 2022
Gainers ION Geophysical Corporation (NYSE: IO) shares surged 29.8% to settle at $0.5969. Synaptogenix, Inc. (NASDAQ: SNPX) climbed 29.4% to close at $10.09. Synaptogenix...
Via
Benzinga
Anavex Life Sciences Crashes As Last-Minute Testing Edits Cloud Drug's Impact
February 01, 2022
Just two weeks ago, Anavex edited the goals of its study in Rett syndrome.
Via
Investor's Business Daily
34 Stocks Moving In Tuesday's Mid-Day Session
February 01, 2022
Gainers Biofrontera Inc. (NASDAQ: BFRI) shares climbed 30.7% to $4.4095 after the company provided an update on patient recruitment for the Phase III study for the treatment of...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
February 01, 2022
Gainers Windtree Therapeutics (NASDAQ:WINT) stock rose 25.6% to $1.42 during Tuesday's regular session. Trading volume for Windtree Therapeutics's stock is 652.4K...
Via
Benzinga
Mid-Day Market Update: Pitney Bowes Drops After Q4 Earnings; Biofrontera Shares Climb
February 01, 2022
US stocks traded mostly flat on Tuesday after recording sharp gains in the previous session. Wall Street closed the volatile January month with steep losses.
Via
Benzinga
Mid-Morning Market Update: Markets Mostly Lower Following Monday's Rally; UPS Earnings Top Views
February 01, 2022
US stocks started the first trading day of new month on a cautious note after recording gains on Monday. Wall Street closed the volatile January month with steep losses.
Via
Benzinga
The Daily Biotech Pulse: ImmunityBio Reports Positive Readout, Valneva Starts Late-Stage Chikungunya Vaccine Study, Sio Gene Shelves Parkinson's Program
February 01, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
January 14, 2022
Gainers Molecular Partners (NASDAQ:MOLN) shares moved upwards by 11.9% to $31.66 during Friday's pre-market session. The market value of their outstanding shares is at...
Via
Benzinga
Anavex Life's Neurodegenerative Disease Candidate Meets Primary Endpoint In Early-Stage Study
January 10, 2022
Anavex Life Sciences Corp (NASDAQ: AVXL) announced topline results from its Phase 1 trial of ANAVEX3-71 in development for neurodegenerative diseases, including...
Via
Benzinga
The Week Ahead In Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts In Focus
December 26, 2021
Biopharma stocks eked out modest gains in the week ending Dec. 23, with regulatory decisions, clinical readouts, and COVID-19 treatment and vaccine developments dictating sentiment. Here are the key...
Via
Talk Markets
The Week Ahead In Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts In Focus In Final Week Of Year
December 26, 2021
Biopharma stocks eked out modest gains in the week ending Dec. 23, with regulatory decisions, clinical readouts and COVID-19 treatment and vaccine developments dictating...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
November 24, 2021
Gainers iSpecimen (NASDAQ:ISPC) shares in...
Via
Benzinga
The Daily Biotech Pulse: Kura's Blood Cancer Drug Study Gets Partial Clinical Hold, Takeda FDA Nod, Puma Breast Cancer Treatment Gets Patent Extension
November 24, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Puma Biotech Announces Receipt Of Patent Extension For Breast Cancer Drug By...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Earnings Scheduled For November 24, 2021
November 24, 2021
Companies Reporting Before The Bell • Centogene (NASDAQ:CNTG) is likely to report quarterly loss at $0.55 per share on revenue of $31.75 million. • Anavex Life...
Via
Benzinga
Earnings Outlook For Anavex Life Sciences
November 23, 2021
Anavex Life Sciences (NASDAQ:AVXL) is set to give its latest quarterly earnings report on Wednesday, 2021-11-24. Here's what investors need to know before the announcement....
Via
Benzinga
The Week Ahead In Biotech (Nov. 21-Nov. 27): FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week
November 21, 2021
Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the winding down of the reporting...
Via
Talk Markets
Exposures
Product Safety
The Week Ahead In Biotech (Nov. 21-Nov. 27): Takeda, Aadi, Fennec FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week
November 21, 2021
Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the...
Via
Benzinga
Exposures
Product Safety
12 Health Care Stocks Moving In Monday's Pre-Market Session
November 01, 2021
Gainers Artelo Biosciences (NASDAQ:ARTL) stock moved upwards by 55.11% to $1.11 during Monday's pre-market session. The company's market cap stands at $27.1...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 23, 2021
September 23, 2021
Upgrades Barclays upgraded the previous rating for Warner Music Group Corp (NASDAQ:
Via
Benzinga
Why Is Biogen Pursuing a New Direction in Alzheimer's Research?
August 13, 2021
It might be that Biogen, too, is abandoning the theory that amyloid plaque is the cause of the disease.
Via
The Motley Fool
Anavex Life Sciences (AVXL) Q3 2021 Earnings Call Transcript
August 13, 2021
AVXL earnings call for the period ending June 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Earnings Scheduled For August 12, 2021
August 12, 2021
Companies Reporting Before The Bell • Anavex Life Sciences (NASDAQ:AVXL) is estimated to report earnings for its third quarter. • ITeos Therapeutics (NASDAQ:ITOS...
Via
Benzinga
70 Biggest Movers From Yesterday
July 30, 2021
Gainers Xenetic Biosciences, Inc. (NASDAQ: XBIO) shares surged 65.1% to settle at $5.30 on Thursday. Xenetic Biosciences recently reported closing of $12.5 million private...
Via
Benzinga
Here's Why Annovis Bio, Anavex Life Sciences, and Cassava Sciences Sank on Thursday
July 29, 2021
A clinical-trial flop for Annovis Bio is reminding investors that developing new drugs for Alzheimer's disease is an extremely risky business.
Via
The Motley Fool
12 Health Care Stocks Moving In Thursday's Intraday Session
July 29, 2021
Gainers NanoVibronix (NASDAQ:NAOV) share...
Via
Benzinga
Anavex Life's Stock Declines Despite Data Shows Alzheimer's Candidate Prevent Abeta-Induced Cognitive Decline In Animal Study
July 29, 2021
Anavex Life Sciences Corp (NASDAQ: AVXL) has reported new preclinical data for its Alzheimer's candidate, ANAVEX2-73 (blarcamesine). Pre-treatment with...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.